Pfizer-BioNTech to commence late stage study of COVID-19 vaccine candidate
The study is expected to include about 120 sites globally and up to 30,000 participants
BioNTech and Pfizer informed they would begin the Phase2/3 trial to evaluate their COVID-19 vaccine candidate. If the study is successful, the companies could submit the vaccine for regulatory approval as early as October, putting them on track to supply up to 100 million doses by the end of 2020 and 1.3 billion by the end of 2021.
Patients are each given two doses of the drugmakers’ vaccine to help boost immunity, so the first 100 million doses would vaccinate around 50 million people.
The study is expected to include about 120 sites globally and could include up to 30,000 participants. It will include regions heavily impacted by COVID-19.
“The initiation of the Phase 2/3 trial is a major step forward in our progress toward providing a potential vaccine to help fight the ongoing COVID-19 pandemic,” said Kathrin Jansen, head of vaccine research and development at Pfizer.
The trial hones in on Pfizer’s most promising vaccine candidate, which it calls BNT162b2. Earlier studies filtered out other potential vaccines.
Pfizer already has an agreement to sell 100 million doses of its vaccine to the US government and give it the option to buy 500 million more. It is in talks with other governments, including the European Union, about similar deals.
The vaccine utilises chemical messenger RNA to mimic the surface of the coronavirus and teach the immune system to recognise and neutralise it. Although the technology has been around for years, there has never been an approved messenger RNA (mRNA) vaccine.